Vikram Patney Diabetc, Adam Whaley-ConnellGeorge Bakris; Hypertension Management in Diabetic Kidney Disease. Diabetes Spectr 1 August ; preasure 3 : — IN Nephrooathy Hypertension is prevalent in most individuals bllod diabetic kidney nelhropathy DKD.
Failure to treat hypertension appropriately in pressyre subgroup of patients ptessure in an increased risk of cardiovascular morbidity and mortality, as nepyropathy as a faster progression of kidney disease. The current guidance for appropriate treatment of hypertension Youthful glow this high-risk population provides nepropathy opportunity to ppressure both kidney and cardiovascular outcomes.
This review discusses the current state of nepropathy hypertension management in patients nepyropathy DKD. The Diabrtic diabetes epidemic is growing and is largely attributable to the rising incidence Diaebtic obesity.
Moreover, the rising preesure of obesity is driving pressrue higher bpood of hypertension and kidney disease that contributes to a growing risk of cardiovascular morbidity and mortality among those with diabetes. Although incident Body recomposition results for end-stage renal Refreshment Delivery Services ESRD may have stabilized nrphropathy the past few years 12prevalence rates Diabetic nephropathy blood pressure control cardiovascular mortality attributable blod diabetic kidney disease DKD have not 2.
In Extract recipe data regard, management of hypertension in this high-risk population contributes Diabetic nephropathy blood pressure control nephropatyy the reduction of the cardiovascular disease CVD burden in DKD 3 nlood, 4.
Hypertension is highly Antiviral disease resistance in individuals with DKD and occurs Diabetic nephropathy blood pressure control as often as nelhropathy the general Citrus oil for reducing inflammation 3.
There preswure a strong, continuous relationship blkod reductions in glomerular filtration rate GFR bkood subsequent cardiovascular event rates after conntrol such as an acute myocardial Diaabetic MI 6. Hlood is not only the Diabetic coma prevention tips that is of concern, but also nephhropathy morbidity and high overall costs conhrol care related to DKD.
This is in conyrol part the result of the strong association of DKD with CVD outcomes such as heart failure, Diagetic, MI, and ESRD blooc. In jephropathy with type 1 diabetes, albuminuria or overt nephropathy generally precedes the appearance Diabdtic hypertension Natural weight management. However, in Diaebtic 2 diabetes, hypertension in most cases antedates development of nephropatby and reductions in estimated GFR eGFR because of shared risk factors, including the presence of Mindfulness practices, dyslipidemia, and cardiorenal Nutrient-dense cooking oils syndrome.
Pressrue are multiple mechanisms in the development pressurr hypertension in patients bpood DKD, jephropathy inappropriate activation Diabtic the renin angiotensin bephropathy system RAAS nephripathy the sympathetic nervous system, volume expansion due to increased sodium reabsorption, peripheral vasoconstriction, Diabwtic of endothelin 1, inflammation and conhrol of reactive oxygen species, and downregulation nephropahy nitric oxide 9.
Many of these factors accelerate the Diabeti of bloid disease pressuge increase Diabetuc risk for CVD among people with Taurine supplements and contrpl 8.
Thus, pressurr serve as targets for risk reduction by managing hypertension. However, the target BP for the management of hypertension prsssure not as clear; few Resveratrol and arthritis trials have assessed different BP levels prexsure people bloox diabetic nephropathy, and one failed bkood demonstrate presshre benefit of lower BP on cardiovascular risk reduction 10 — There is neohropathy controversy regarding the Expert Panel report JNC-8 11 prexsure the management of cpntrol in those with diabetes, as well as those with kidney disease.
This recommendation was based on expert Diabetic nephropathy blood pressure control, as presssure were only two trials in CrossFit workouts with diabetes randomizing Appetite control goals to Replenishing after workout levels and evaluating cardiovascular outcomes.
The Expert Panel relied on moderate-quality evidence from two trials: prsesure U, Diabetic nephropathy blood pressure control. Prospective Diabetes Study UKPDS and Diabtic Action to Control Cardiovascular Risk in Diabetes neephropathy pressure trial Presxure.
The ACCORD-BP, which was specifically designed to investigate BP targets in the range of mmHg systolic, failed to demonstrate bliod cardiovascular risk boood compared bloof a standard mmHg target Only Dkabetic trial provides evidence for benefit of a diastolic BP target blold 80 mmHg.
This benefit is derived from a post hoc analysis contrl the diabetes subgroup of the Hypertension Optimal Natural metabolism-boosting drinks HOT nphropathy, in which the subgroup of those with nephropatby randomized to Diaabetic mmHg had a reduction in composite CVD outcomes It is notable contrrol, in the HOT congrol, there were Nephropaty patients with DKD.
Hence, although this Conttol level can be a goal, the evidence supporting its benefit on Nephrooathy progression is very pressure. Data from cohorts of patients with diabetes that support a pressuree BP goal come from cintrol one randomized, single-center Diqbetic and DKA symptoms list observational studies The randomized trial was the Liver wellness products Study, a multiple Diavetic factor nepphropathy trial in Improving skin texture and tone 2 Diabstic Because there are no randomized, multicenter, controlled Nephropatuy available to address appropriate Body size and health targets in nephropaghy with DKD, bloid target BP for patients with contril is commonly used as an alternate.
In addition, the ADA consensus panel 17 pointed out the relevance of hour ambulatory BP measurement to identify at-risk subgroups of patients with diabetes, such as those with masked hypertension and nocturnal non-dipping status, as possible confounders of the relationship between office-measured BP and DKD progression The emphasis on treatment of hypertension in patients with DKD should include strategies that address multifactorial risk factor reduction and include pharmacotherapy, lifestyle modification, and patient education to improve self-management of these complex risk factors.
Such strategies often require innovative team-based approaches involving primary care providers, endocrinologists, nephrologists, nutritionists, pharmacists, nurse educators, mid-level providers, and mental health professionals.
Integrated health care delivery systems, patient-centered medical homes, and accountable care organizations may provide the organizational structure to provide such multidisciplinary team-based care. A small study from the United Kingdom suggests that self-management techniques such as understanding, and subsequently adhering to, the prescribed BP medication regimen may contribute to a reduction in BP, which in turn will reduce cardiovascular risk Strategies should target smoking cessation, diet modification, exercise, and weight loss, with the ultimate aim of reducing both CVD risk and DKD progression.
The recent double-blind, placebo-controlled, randomized crossover trial called LowSALT CKD Phase 1 assessed the effect of sodium restriction on ambulatory BP and other cardiovascular risk factors In addition, considerable reductions in extracellular volume and albuminuria occurred, and albuminuria reduction occurred independent of BP changes.
The level to which sodium intake should be restricted is of considerable debate. The possibility of hyperkalemia secondary to high potassium intake in DASH Dietary Approaches to Stop Hypertension —type diets in patients with late-stage CKD is also a consideration in people with diabetes.
Moderation of alcohol intake, weight loss, and increased physical activity as recommended by the current ADA standards of care are all beneficial for management of hypertension in patients with DKD This section integrates recommendations from the JNC-7, KDIGO, and Expert Panel report, as well as the ADA guidelines.
If a patient has end-organ injury such as left ventricular hypertrophy and albuminuria, then lifestyle modification and antihypertensive pharmacotherapy should be initiated at the initial visit. In the absence of end-organ injury, a trial of 1—2 months of lifestyle modification alone, especially focusing on sodium intake reduction, should be tried.
If goal BP is not reached through nonpharmacological approaches, then pharmacotherapy should be considered. An updated algorithm from the original National Kidney Foundation consensus report is provided in Figure 1.
An updated general approach for achieving BP goals in people with diabetes. This integrated approach summarizes the National Kidney Foundation consensus report and American Society of Hypertension guidelines 49 ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; K, potassium.
The use of ACE inhibitors or angiotensin II receptor blockers ARBs for RAAS inhibition to reduce albuminuria, cardiovascular risk, and the progression of DKD is well supported by a number of clinical trials 26 — Hence, the Expert Panel, ADA, and KDIGO guidelines recommend ACE inhibitors or ARBs at maximally tolerated doses as first-line therapy for the treatment of hypertension in patients with DKD 11 — Historically, there have been concerns about the residual risk for progression of DKD and cardiovascular outcomes despite maximally dosed ACE inhibitors or ARBs.
In the past decade, a number of investigators have sought to explore whether the combined use of an ACE inhibitor and an ARB may slow CKD progression further than either agent used alone. The trial data clearly demonstrate a lack of benefit and an increased risk of harm, manifested by increased risk for hyperkalemia and acute kidney injury using the combined RAAS approach.
The ONTARGET Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial was a multicenter double-blind, randomized, controlled trial that found combination therapy to be associated with more adverse events without a further reduction in cardiovascular or renal events Therefore, the use of combination RAAS therapy should not be used in people with advanced CKD.
Studies also demonstrate consistently greater reductions in BP and albuminuria when MR blockers are added to an ACE inhibitor or ARB.
However, the use of this combination comes with the risk of hyperkalemia and, hence, should be done with frequent monitoring.
These individuals are at a three- to eightfold increased risk of developing hyperkalemia if an ACE inhibitor or ARB is started. Moreover, if an RAAS blocker is already being used and a mineralocorticoid inhibitor is added with the aforementioned eGFR and potassium values, such patients are at a more than sevenfold higher risk of developing hyperkalemia 35 The ADA consensus conference work group highlighted the remaining gap in our understanding of combination RAAS strategies and the incorporation of MR blockade There has been great interest in the combination of MR blockade with an ACE inhibitor or ARB.
However, in small studies, there has been a signal for increased hyperkalemia risk, and larger trials are needed In this regard, there are novel nonsteroidal MR blockers in development that may provide some insight in the future.
Moreover, potassium binding agents such as patiromer and ZS-9 may reduce the risk of hyperkalemia and allow for future investigation of the various RAAS combinations 38 Nondihydropyridine calcium channel blockers CCBsincluding diltiazem and verapamil, are useful for the treatment of hypertensive patients with DKD.
They may be used as first-line therapy in patients intolerant of ACE inhibitors and ARBs or as second-line agents in combination with an ACE inhibitor or ARB These agents may reduce higher-level albuminuria without an RAAS blocker, but in combination with an ACE inhibitor or ARB, they help to reduce blood pressure while preserving kidney function in people with diabetes Dihydropyridine CCBs such as amlodipine and nifedipine are effective antihypertensive agents but do not reduce proteinuria and cause dose-dependent peripheral edema as a side effect.
They should only be used in conjunction with an RAAS blocker because they do provide benefit in this setting The incidence of peripheral edema may be reduced by using dihydropyridine CCBs in combination with an ACE inhibitor Thiazide or thiazide-like diuretics e.
Although diuretics once were considered initial therapy, recent guidelines now include them with three other drug classes i. The important point is to understand volume status in individuals with DKD; because not all patients have volume issues, using these agents as initial therapy may be of limited value in this population.
Al-though these agents have multiple side effects, including hyperglycemia, dyslipidemia, hyperuricemia, and electrolyte abnormalities, their long-term use with management of these side effects does not adversely affect outcomes Long-acting loop diuretics e.
Endothelin-1 is a potent vasoconstrictor that exerts its effect via the endothelin receptor type A ET A and type B ET B. ET A and ET B are expressed on the renal vascular smooth muscle, whereas ET B predominates in tubular epithelial cells.
Recent clinical studies suggest that selective blockade of the ET A receptor may be beneficial in the treatment of hypertension, diabetes, and proteinuria ET A receptor activation is thought to mediate vasoconstriction, as well as increases in albuminuria and glomerular filtration barrier injury.
Conversely, ET B receptor activation promotes vasodilatation and clearance of endothelin A recent trial evaluating the benefits of the ET A receptor antagonist avosentan in diabetic nephropathy had to be terminated prematurely because of safety concerns related to fluid overload. However, avosentan did show some beneficial effect in reducing proteinuria The DORADO trial studied the use of darusentan a selective ET A receptor antagonist and found a dose-dependent reduction of systolic BP Atrasentan is another selective ET A receptor antagonist that has shown significant BP reduction in a recent randomized, controlled trial However, none of these drugs has been approved by the U.
Food and Drug Administration for the treatment of hypertension. Further study may be needed to resolve issues with side effects, including fluid overload, as well as hepatotoxicity with some of the drugs.
Device therapy targeting the sympathetic nervous system for the treatment of hypertension is another novel approach. Renal denervation involves ablating sympathetic nerves in renal arteries by using a catheter to deliver radiofrequency energy of low power to the endothelial layer.
Unfortunately, its results did not demonstrate a significant reduction of BP in these patients at 6 months. An updated technique and other changes will lead to future clinical trials using this procedure.
Baroreflex activation therapy is also being studied as a device-based, nonpharmacological treatment in patients with resistant hypertension. The activation of these stretch baroreceptors leads to inhibition of sympathetic output, which then leads to decreased heart rate, cardiac contractility, reduced secretion of antidiuretic hormone, and thus decreased intravascular volume and tone Unlike renal denervation, the effectiveness of baroreflex activation can be assessed immediately after device implantation These devices show promising early results but require further study regarding efficacy and safety before being approved for use in the treatment of hypertension.
In summary, there have been many improvements in the understanding and treatment of diabetic nephropathy over the past 30 years.
: Diabetic nephropathy blood pressure control| Introduction | Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Questions to regularly review with your doctor or other members of the team include:. Microalbuminuria Collaborative Study Group, United Kingdom. Agarwal R. This increased risk for the renal outcomes with either the SBP or PP is diminished, however, after adjusting for other risk factors. Basu S, Sussman JB, Rigdon J, Steimle L, Denton BT, Hayward RA. |
| Epidemiology of Hypertension in Diabetic Nephropathy | J Pharmacol Exp Ther ; : — Target Blood Pressure for People With DKD. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Conversely, ET B receptor activation promotes vasodilatation and clearance of endothelin Pro renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. If goal BP is not reached through nonpharmacological approaches, then pharmacotherapy should be considered. |
| Pathophysiology of Hypertension in DKD | Riser BL, Ladson-Wofford S, Sharba A, Cortes P, Drake K, Guerin CJ, Yee J, Choi ME, Segarini PR, Narins RG. TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int ; 56 : — Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol ; 11 : 25— Giunti S, Pinach S, Arnaldi L, Viberti G, Perin PC, Camussi G, Gruden G. Kidney Int ; 69 : — Gruden G, Setti G, Hayward A, Sugden D, Duggan S, Burt D, Buckingham RE, Gnudi L, Viberti G. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant proteinmediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol ; 16 : — Kuroiwa T, Lee EG, Danning CL, Illei GG, McInnes IB, Boumpas DT. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. J Immunol ; : — Mene P, Pugliese F, Cinotti GA. Adhesion of U monocytes induces cytotoxic damage and subsequent proliferation of cultured human mesangial cells. Kidney Int ; 50 : — Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L, Viberti G. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol ; 10 : — Thomas S, Vanuystel J, Gruden G, Rodríguez V, Burt D, Gnudi L, Hartley B, Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol ; 11 : — Amemiya T, Sasamura H, Mifune M, Kitamura Y, Hirahashi J, Hayashi M, Saruta T. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Gnudi L, Viberti G, Raij L, Rodriguez V, Burt D, Cortes P, Hartley B, Thomas S, Maestrini S, Gruden G. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension ; 42 : 19— Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest ; 96 : — Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant ; 19 : — Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol ; 12 : — Endlich N, Endlich K. Stretch, tension and adhesion- adaptive mechanisms of the actin cytoskeleton in podocytes. Eur J Cell Biol ; 85 : — Dessapt C, Baradez MO, Hayward A, Dei Cas A, Thomas SM, Viberti G, Gnudi L. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant ; 24 : — Patey N, Halbwachs-Mecarelli L, Droz D, Lesavre P, Noel LH. Distribution of integrin subunits in normal human kidney. Cell Adhes Commun ; 2 : — Ruoslahti E. J Clin Invest ; 87 : 1—5. Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol ; : F—F Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int ; 65 : 30— Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G. Stretch reduces nephrin expression via an angiotensin II-AT 1 -dependent mechanism in human podocytes: effect of rosiglitazone. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes ; 52 : — Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Amazonas RB, Sanita Rde A, Kawachi H, de Faria JB. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus. Nephron Physiol ; : 57— Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD P H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes ; 55 : — Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes ; 54 : — Jones DP. Redefining oxidative stress. Antioxid Redox Signal ; 8 : — Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol ; : — Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia ; 42 : — Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, Kukidome D, Wake N, Matsumura T, Miyamura N, Sakakida M, Kishikawa H, Araki E. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care ; 26 : — Hinokio Y, Suzuki S, Hirai M, Suzuki C, Suzuki M, Toyota T. Diabetologia ; 45 : — Wang Q, Pfister F, Dorn-Beineke A, vom Hagen F, Lin J, Feng Y, Hammes HP. Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia ; 53 : — Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis ; 21 : — Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int ; 63 : — Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, Usui H, Nagase R, Ogawa D, Okada S, Shikata Y, Wada J, Makino H. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia ; 48 : — Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, Okada S, Wada J, Nagase R, Ogawa D, Shikata Y, Makino H. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H. Intercellular adhesion moleculedeficient mice are resistant against renal injury after induction of diabetes. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int ; 69 : 73— Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res ; : McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol ; : — Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med ; 22 : — Silva KC, Pinto CC, Biswas SK, Souza DS, de Faria JB, de Faria JM. Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. Exp Eye Res ; 85 : — Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov ; 8 : — Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol ; 2 : — Biswas SK, Peixoto EB, Souza DS, de Faria JB. Hypertension increases pro-oxidant generation and decreases antioxidant defense in the kidney in early diabetes. Am J Nephrol ; 28 : — DeRubertis FR, Craven PA, Melhem MF, Salah EM. Diabetes ; 53 : — Fujita H, Fujishima H, Chida S, Takahashi K, Qi Z, Kanetsuna Y, Breyer MD, Harris RC, Yamada Y, Takahashi T. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol ; 20 : — Peixoto EB, Pessoa BS, Biswas SK, Lopes de Faria JB. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension. Am J Nephrol ; 29 : — Ribaldo PD, Souza DS, Biswas SK, Block K, Lopes de Faria JM, Lopes de Faria JB. Green tea Camellia sinensis attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J Nutr ; : 96— Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res ; 32 : — Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord ; 9 : — Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem ; 80 : — Pinto CC, Silva KC, Biswas SK, Martins N, De Faria JB, De Faria JM. Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy. Free Radic Res ; 41 : — Rosales MA, Silva KC, Lopes de Faria JB, Lopes de Faria JM. Exogenous SOD mimetic tempol ameliorates the early retinal changes restablishing the redox status in diabetic hypertensive rats. Invest Ophthalmol Vis Sci ; 51 : — Silva KC, Rosales MA, de Faria JB, de Faria JM. Reduction of inducible nitric oxide synthase via angiotensin receptor blocker prevents the oxidative retinal damage in diabetic hypertensive rats. Curr Eye Res ; 35 : — Silva KC, Rosales MA, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes ; 58 : — Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther ; : — Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl ; 63 : S—S Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens ; 17 : 16S—20S. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med ; : 40— Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, DIRECT Programme Study Group. Effect of candesartan on prevention DIRECT-Prevent 1 and progression DIRECT-Protect 1 of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet ; : — Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol ; 17 : — Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N. DIRECT programme study group: effect of candesartan on progression and regression of retinopathy in type 2 diabetes DIRECT-Protect 2 : a randomized placebo-controlled trial. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant ; 24 : 73— Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int ; 66 : — Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetics rats. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab ; 91 : — Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucosephosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol ; : — Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J. Glucosephosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J ; 15 : — Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. Glucosephosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol ; 23 : — Xu Y, Zhang Z, Hu J, Stillman IE, Leopold JA, Handy DE, Loscalzo J, Stanton RC. Glucosephosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FASEB J ; 24 : — Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucosephosphate dehydrogenase activity. Nat Med ; 13 : — Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: insights into its molecular and patho physiological biology. Nucl Recept Signal ; 5 : e Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res ; : — Castro-Chaves P, Cerqueira R, Pintalhao M, Leite-Moreira AF. New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. Expert Opin Ther Targets ; 14 : — Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes ; 59 : — Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI, Cooper ME. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res ; 29 : — Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther ; 25 : 23— Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab ; 15 : — Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin converting enzyme 2 in diabetic nephropathy. Hypertension ; 41 : — Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzymerelated carboxypeptidase ACE2 converts angiotensin I to angiotensin 1—9. Circ Res ; 87 : E1—E9. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int ; 74 : — Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, Li KT, Szeto CC. Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D. ACE and ACE2 activity in diabetic mice. Shiota A, Yamamoto K, Ohishi M, Tatara Y, Ohnishi M, Maekawa Y, Iwamoto Y, Takeda M, Rakugi H. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens Res ; 33 : — Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. J Clin Invest ; : — Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, Binger KJ, Campbell DJ, Miller AG. Hypertension ; 55 : — Wilkinson-Berka JL, Campbell DJ. Pro renin receptor: a treatment target for diabetic retinopathy? Wilkinson-Berka JL. Prorenin and the pro renin receptor in ocular pathology. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and pro renin receptor expression in diabetic TG mRen-2 27 rats. Hypertension ; 52 : — Hsueh WA, Baxter JD. Human prorenin. Hypertension ; 17 : — Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab ; 68 : — Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ, Skinner SL. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci ; 36 : — Campbell DJ. Critical review of prorenin and pro renin receptor research. Hypertension ; 51 : — Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H. Regression of nephropathy developed in diabetes by Pro renin receptor blockade. J Am Soc Nephrol ; 18 : — Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced Pro renin receptor expression. Endocrinology ; : — Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S. Pro renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Tang Z, Shou I, Wang LN, Fukui M, Tomino Y. Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes. Nephron ; 76 : — Ogawa S, Kobori H, Ohashi N, Urushihara M, Nishiyama A, Mori T, Ishizuka T, Nako K, Ito S. Angiotensin II Type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with Type 2 Diabetic nephropathy. Biomark Insights ; 4 : 97— United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS Ruggenenti P, Cravedi P, Remuzzi G, Medscape. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol ; 6 : — Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol ; 38 : — Silva PS, Cavallerano JD, Sun JK, Aiello LM, Aiello LP. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol ; 6 : — Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy. Metabolism ; 58 : — Taubert D, Roesen R, Lehmann C, Jung N, Schömig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA ; : 49— Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, Strauch C, Du Y, Tang J, Kern TS, Lederer MO, Brownlee M, Weiss MF, Monnier VM. Paradoxical effects of green tea Camellia sinensis and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Download references. This work was supported by the State of São Paulo Research Foundation Fapesp and National Council for Scientific and Technological Development CNPq. Department of Internal Medicine, Renal Pathophysiology Laboratory, Investigation in Diabetes Complications, Faculty of Medical Sciences, University of Campinas Unicamp , Campinas, São Paulo, Brazil. You can also search for this author in PubMed Google Scholar. Correspondence to José Butori Lopes de Faria. Reprints and permissions. Lopes de Faria, J. The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertens Res 34 , — Download citation. Received : 02 June Revised : 10 September Accepted : 04 October Published : 13 January Issue Date : April Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Graefe's Archive for Clinical and Experimental Ophthalmology Skip to main content Thank you for visiting nature. nature hypertension research review article. Download PDF. Subjects Diabetes complications Hypertension Pathogenesis. Abstract Diabetes and hypertension frequently coexist and constitute the most notorious combination for the pathogenesis of diabetic nephropathy and retinopathy. Controlled diabetes amends oxidative stress as mechanism related to severity of diabetic retinopathy Article Open access 03 September Correlations among Diabetic Microvascular Complications: A Systematic Review and Meta-analysis Article Open access 28 February Different characteristics of retinal damage between chronic hypertension and hypertensive retinopathy Article Open access 07 November Introduction The incidence and prevalence of hypertension among diabetic patients have been documented in various populations; overall, hypertension occurs 1. Clinical and epidemiological evidence of the detrimental effect of hypertension on diabetic nephropathy and retinopathy In individuals with diabetes mellitus DM , the relationship between hypertension and poor vascular outcomes, including diabetic renal and retinal diseases, is unequivocal and independent of other confounding factors. Experimental evidence that hypertension aggravates diabetic nephropathy and retinopathy Many studies have demonstrated that the presence of hypertension aggravates and can contribute to renal and retinal disease in experimental DM. In vitro studies searching for the mechanism of the interaction of hypertension and diabetes in diabetic nephropathy and retinopathy Clinical and experimental works suggest that systemic hypertension leading to increased intraglomerular pressure contributes to glomerular sclerosis in several renal diseases. Contribution of inflammation and oxidative stress to DR and nephropathy Both oxidative stress and inflammation have been strongly implicated in the pathogenesis of diabetic complications. Inflammation and oxidative stress as the underlying mechanism for the interaction between hypertension and DR and nephropathy Both hypertension and diabetes induce oxidative stress and inflammation, which, in turn, contribute to diabetic nephropathy and retinopathy Figure 1. Full size image. Role of renin—Ang aldosterone system with emphasis on aldosterone, Ang-converting enzyme 2 and prorenin in DR and nephropathy The link between hypertension and the pathogenesis and progression of DR and nephropathy most likely involves the renin—Ang aldosterone system RAAS. Concluding remarks Blood glucose control, normalization of arterial pressure and use of drugs that interfere in the RAAS are efficient approaches for the prevention and treatment of diabetic nephropathy and retinopathy. Similar content being viewed by others. References Anonymous. Google Scholar Geiss LS, Rolka DB, Engelgau MM. Google Scholar Jensen T, Borch-Johnsen K, Deckert T. CAS Google Scholar Parving HH. Google Scholar Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. CAS Google Scholar Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. CAS Google Scholar The UKPDS Study Group. Google Scholar Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F, ADVANCE Collaborative Group. CAS Google Scholar Giunti S, Barit D, Cooper ME. CAS Google Scholar Schrier RW, Estacio RO, Esler A, Mehler P. Google Scholar Thomas MC, Atkins RC. CAS Google Scholar Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. Google Scholar Klein R, Lee KE, Gangnon RE, Klein BE. Google Scholar Rodrigues TC, Canani LH, Viatroski RS, Hoffmann LH, Esteves JF, Gross JL. Google Scholar Körner A, Jaremko G, Eklöf AC, Aperia A. Google Scholar Mauer SM, Steffes MW, Azar S, Sandberg SK, Brown DM. CAS Google Scholar Wakisaka M, Nunoi K, Iwase M, Kikuchi M, Maki Y, Yamamoto K, Sadoshima S, Fujishima M. CAS Google Scholar Cooper ME, Allen TJ, O'Brien RC, Macmillan PA, Clarke B, Jerums G, Doyle AE. CAS Google Scholar Dosso AA, Leuenberger PM, Rungger-Brändle E. CAS Google Scholar Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. CAS Google Scholar Gin T, Joon TL, Panagiotopoulos S, Cooper M, Taylor H, Jerums G. CAS Google Scholar Righetti AE, Boer-Lima PA, Lopes de Faria JB. CAS Google Scholar Lopes de Faria JM, Silva KC, Boer PA, Cavalcanti TC, Rosales MA, Ferrari AL, Lopes de Faria JB. CAS Google Scholar Wolf G. CAS Google Scholar Wolf G, Schroeder R, Thaiss F, Ziyadeh FN, Helmchen U, Stahl RA. CAS Google Scholar Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. CAS Google Scholar Silveira LA, Bacchi CE, Pinto GA, De Faria JB. Conversely, ET B receptor activation promotes vasodilatation and clearance of endothelin A recent trial evaluating the benefits of the ET A receptor antagonist avosentan in diabetic nephropathy had to be terminated prematurely because of safety concerns related to fluid overload. However, avosentan did show some beneficial effect in reducing proteinuria The DORADO trial studied the use of darusentan a selective ET A receptor antagonist and found a dose-dependent reduction of systolic BP Atrasentan is another selective ET A receptor antagonist that has shown significant BP reduction in a recent randomized, controlled trial However, none of these drugs has been approved by the U. Food and Drug Administration for the treatment of hypertension. Further study may be needed to resolve issues with side effects, including fluid overload, as well as hepatotoxicity with some of the drugs. Device therapy targeting the sympathetic nervous system for the treatment of hypertension is another novel approach. Renal denervation involves ablating sympathetic nerves in renal arteries by using a catheter to deliver radiofrequency energy of low power to the endothelial layer. Unfortunately, its results did not demonstrate a significant reduction of BP in these patients at 6 months. An updated technique and other changes will lead to future clinical trials using this procedure. Baroreflex activation therapy is also being studied as a device-based, nonpharmacological treatment in patients with resistant hypertension. The activation of these stretch baroreceptors leads to inhibition of sympathetic output, which then leads to decreased heart rate, cardiac contractility, reduced secretion of antidiuretic hormone, and thus decreased intravascular volume and tone Unlike renal denervation, the effectiveness of baroreflex activation can be assessed immediately after device implantation These devices show promising early results but require further study regarding efficacy and safety before being approved for use in the treatment of hypertension. In summary, there have been many improvements in the understanding and treatment of diabetic nephropathy over the past 30 years. It is clear that, in advanced nephropathy with very high albuminuria, RAAS blockade has been a key factor in slowing disease progression along with attaining better blood pressure control. Newer medications and approaches continue to be investigated as well. No other potential conflicts of interest relevant to this article were reported. Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Diabetes Spectrum. Advanced Search. User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation. Volume 28, Issue 3. Previous Article Next Article. Pathophysiology of Hypertension in DKD. Target Blood Pressure for People With DKD. Approach to Therapy. Risk Factor Reduction and Lifestyle Modification. Duality of Interest. Article Navigation. From Research to Practice August 01 Hypertension Management in Diabetic Kidney Disease Vikram Patney ; Vikram Patney. This Site. Google Scholar. Adam Whaley-Connell ; Adam Whaley-Connell. George Bakris George Bakris. Corresponding author: George Bakris, MD, gbakris gmail. Diabetes Spectr ;28 3 — Get Permissions. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. FIGURE 1. View large Download slide. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U. continues to decline. Search ADS. Changes in diabetes-related complications in the United States, — Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS Effect of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Accessed 14 May Prevalence of hypertension in type 1 insulin dependent diabetes mellitus. Van Buren. Hypertension in diabetic nephropathy: epidemiology, mechanisms and management. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. KDIGO clinical practice guidelines for the management of blood pressure in chronic kidney disease. American Diabetes Association. Cardiovascular disease and risk management. The Action to Control Cardiovascular Risk in Diabetes ACCORD blood pressure trial. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment HOT randomized trial. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program KEEP. Effect of a multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. An evaluation of a self-management package for people with diabetes at risk of chronic kidney disease. Institute of Medicine. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care and immunization. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Combined angiotensin inhibition for the treatment of diabetic nephropathy. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk the ONTARGET study : a multicenter, randomised, double-blind, controlled trial. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. Differential effects of calcium antagonist sub-classes on markers of nephropathy progression. Management of hypertensive chronic kidney disease: role of calcium channel blockers. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Hypertension and new treatment approaches targeting the sympathetic nervous system. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4. View Metrics. |
Ich denke, dass es der ernste Fehler ist.